BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16149603)

  • 1. [CA15-3].
    Inaji H
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():651-3. PubMed ID: 16149603
    [No Abstract]   [Full Text] [Related]  

  • 2. A prospective evaluation of CA15-3 in stage I carcinoma of the breast.
    O'Hanlon DM; Kerin MJ; Kent PJ; Skehill R; Maher D; Grimes H; Given HF
    J Am Coll Surg; 1995 Feb; 180(2):210-2. PubMed ID: 7850057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Squamous cell carcinoma antigen].
    Nawata S; Sugino N; Kato H
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():684-6. PubMed ID: 16149611
    [No Abstract]   [Full Text] [Related]  

  • 4. [CA19-9].
    Odagiri E
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():642-4. PubMed ID: 16149600
    [No Abstract]   [Full Text] [Related]  

  • 5. [Immunoradiometric assay of tumor marker CA15-3 and its clinical application].
    Chen Z; Fan Z; Yang J
    Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):125-8. PubMed ID: 10920962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [STN (sialyl Tn antigen)].
    Kannagi R
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():659-62. PubMed ID: 16149605
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor markers in breast cancer].
    Inaji H; Komoike Y; Motomura K; Koyama H
    Nihon Rinsho; 2000 Apr; 58 Suppl():140-5. PubMed ID: 11025987
    [No Abstract]   [Full Text] [Related]  

  • 9. [BCA225].
    Kumamoto K; Kannagi R
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():669-71. PubMed ID: 16149607
    [No Abstract]   [Full Text] [Related]  

  • 10. Serological tumor markers for monitoring breast cancer.
    Sölétormos G
    Dan Med Bull; 2001 Nov; 48(4):229-55. PubMed ID: 11767127
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CA15-3].
    Matsui A; Ikeda T; Masamura S; Kitajima M
    Nihon Rinsho; 1999 Dec; 57 Suppl():474-7. PubMed ID: 10778168
    [No Abstract]   [Full Text] [Related]  

  • 13. [NCC-ST-439].
    Sugano K
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():681-3. PubMed ID: 16149610
    [No Abstract]   [Full Text] [Related]  

  • 14. [CYFRA21-1].
    Kitamura S
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():654-8. PubMed ID: 16149604
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
    Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
    Ławicki S; Szmitkowski M; Wojtukiewicz M
    Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer].
    Feng J; Hu LH; Lu J; Li YR; Xie F
    Ai Zheng; 2009 Apr; 28(4):436-40. PubMed ID: 19622308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. False elevation of serum CA 15-3 levels in patients under follow-up for breast cancer.
    Aguiar-Bujanda D; Bohn-Sarmiento U; Aguiar-Morales J
    Breast J; 2004; 10(4):375-6. PubMed ID: 15239804
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
    Murray A; Willsher P; Price MR; Dixon AR; Robertson JF
    Anticancer Res; 1997; 17(3C):1945-9. PubMed ID: 9216649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.